Incretin May Raise Pancreatic Cancer Risk, But Only in Short Term

Share this content:
The risk of pancreatic cancer is increased in recent starters of incretins, but the elevated risk drops to baseline levels with prolonged use.
The risk of pancreatic cancer is increased in recent starters of incretins, but the elevated risk drops to baseline levels with prolonged use.

The risk of pancreatic cancer is increased in recent starters of incretins, but the elevated risk drops to baseline levels with prolonged use, according to a study published in Diabetes, Obesity and Metabolism.

Lotte M. Knapen, from Maastricht University Medical Center in the Netherlands, and colleagues examined the correlation between incretin agent use and risk of pancreatic cancer in a retrospective population-based cohort study.

A total of 182,428 patients with at least one non-insulin antidiabetic drug (NIAD) prescription were matched to control patients without diabetes.

The researchers also used a new user design to estimate the hazard ratio of pancreatic cancer in 28,370 incretin users compared with patients without diabetes and other NIAD-treated patients

The researchers found that the risk of pancreatic cancer was increased fourfold with current NIAD use (hazard ratio, 4.28; 95 percent confidence interval, 3.49 to 5.24).

Current incretin users had almost double the risk compared with controls. Compared to controls with diabetes, incretin use was not associated with pancreatic cancer (hazard ratio, 1.36; 95 percent confidence interval, 0.94 to 1.96).

However, in the new user design, there was a correlation between incretin use and pancreatic cancer. The risk of pancreatic cancer almost doubled in recent starters of incretin in cohorts with both prevalent and incident users of anti-diabetic drugs; with prolonged use, the risk decreased to baseline levels.

RELATED: Adding Vismodegib to Gemcitabine Fails to Provide Benefit for Pancreatic Cancer

"The presence of considerable confounding by disease severity and the lack of duration of use relationship do not support a causal explanation for the association between incretin agents and pancreatic cancer," the authors write.

Some authors disclosed institutional funding from industry, including pharmaceutical companies.

Reference

  1. Knapen LM, van Dalen J, Keulemans YC, et al. Use of Incretin Agents and Risk of Pancreatic Cancer: A Population-Based Cohort Study. Diabetes, Obesity and Metabolism. November 2015. DOI: 10.1111/dom.12605.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters